Viatris/VTRS

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Viatris

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Ticker

VTRS

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Canonsburg, United States

Employees

33,000
Website
www.viatris.com

Viatris Metrics

BasicAdvanced
$12B
Market cap
-
P/E ratio
-$0.05
EPS
0.97
Beta
$0.48
Dividend rate
4.60%
Dividend yield
$12B
0.97
$0.48
1.665
0.599
80.305
89.789
-1,024.24%
3.71%
2.71%
-0.27%
0.81
0.62
-1.41
6.25
4.60%
-2.78%
-103.18%
3.74%
-71.82%
63.41%

What the Analysts think about Viatris

Analyst Ratings

Majority rating from 10 analysts.
Hold

Viatris Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
3.10% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$3.7B
-4.53%
Net income
$114M
-114.88%
Profit margin
3.10%
-115.54%

Viatris Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 0.50%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.75
$0.79
$0.62
$0.67
-
Expected
$0.71
$0.74
$0.65
$0.67
$0.68
Surprise
5.59%
6.72%
-4.12%
-0.50%
-

Viatris News

AllArticlesVideos

Viatris Brings to Completion All Previously Announced Divestitures With the Closing of its Over-the-Counter Business Divestiture

PRNewsWire·11 hours ago

US DOJ drops Viatris unit Mylan from industry-wide antitrust probe

Reuters·1 day ago

U.S. Department of Justice Informs Viatris That It No Longer Considers Mylan a Subject of Generic Drug Industry Antitrust Investigation

PRNewsWire·1 day ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Viatris stock?

Viatris (VTRS) has a market cap of $12B as of July 03, 2024.

What is the P/E ratio for Viatris stock?

The price to earnings (P/E) ratio for Viatris (VTRS) stock is 0 as of July 03, 2024.

Does Viatris stock pay dividends?

Yes, the Viatris (VTRS) stock pays dividends to shareholders. As of July 03, 2024, the dividend rate is $0.48 and the yield is 4.6%. Viatris has a payout ratio of -1024.24% on a trailing twelve-month basis.

When is the next Viatris dividend payment date?

The next Viatris (VTRS) dividend payment date is unconfirmed.

What is the beta indicator for Viatris?

Viatris (VTRS) has a beta rating of 0.97. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Viatris stock

Buy or sell Viatris stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing